Fonar Corporation (FONR)vsIDEXX Laboratories Inc (IDXX)
FONR
Fonar Corporation
$18.59
+0.98%
HEALTHCARE · Cap: $92.74M
IDXX
IDEXX Laboratories Inc
$570.21
-1.43%
HEALTHCARE · Cap: $46.09B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 3982% more annual revenue ($4.30B vs $105.43M). IDXX leads profitability with a 24.6% profit margin vs 7.1%. FONR trades at a lower P/E of 13.3x. IDXX earns a higher WallStSmart Score of 61/100 (C+).
FONR
Hold42
out of 100
Grade: D
IDXX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-146.1%
Fair Value
$7.55
Current Price
$18.59
$11.04 premium
Margin of Safety
-40.3%
Fair Value
$462.49
Current Price
$570.21
$107.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Every $100 of equity generates 66 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.8%
Areas to Watch
4.3% revenue growth
Smaller company, higher risk/reward
ROE of 5.8% — below average capital efficiency
7.1% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : FONR
The strongest argument for FONR centers on Price/Book, P/E Ratio.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : FONR
The primary concerns for FONR are Revenue Growth, Market Cap, Return on Equity.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 44.2x leaves little room for execution misses.
Key Dynamics to Monitor
FONR profiles as a value stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.70 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (61/100 vs 42/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?